These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 29605436)

  • 21. Classical molecular dynamics and metadynamics simulations decipher the mechanism of CBP30 selectively inhibiting CBP/p300 bromodomains.
    Wang Q; An X; Xu J; Wang Y; Liu L; Leung EL; Yao X
    Org Biomol Chem; 2018 Sep; 16(35):6521-6530. PubMed ID: 30160288
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery of
    Sheppard GS; Wang L; Fidanze SD; Hasvold LA; Liu D; Pratt JK; Park CH; Longenecker K; Qiu W; Torrent M; Kovar PJ; Bui M; Faivre E; Huang X; Lin X; Wilcox D; Zhang L; Shen Y; Albert DH; Magoc TJ; Rajaraman G; Kati WM; McDaniel KF
    J Med Chem; 2020 May; 63(10):5585-5623. PubMed ID: 32324999
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery, structural insight, and bioactivities of BY27 as a selective inhibitor of the second bromodomains of BET proteins.
    Chen D; Lu T; Yan Z; Lu W; Zhou F; Lyu X; Xu B; Jiang H; Chen K; Luo C; Zhao Y
    Eur J Med Chem; 2019 Nov; 182():111633. PubMed ID: 31461688
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structural investigation of a pyrano-1,3-oxazine derivative and the phenanthridinone core moiety against BRD2 bromodomains.
    Arole AH; Deshmukh P; Sridhar A; Padmanabhan B
    Acta Crystallogr F Struct Biol Commun; 2022 Mar; 78(Pt 3):119-127. PubMed ID: 35234137
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bromodomain-Selective BET Inhibitors Are Potent Antitumor Agents against MYC-Driven Pediatric Cancer.
    Slavish PJ; Chi L; Yun MK; Tsurkan L; Martinez NE; Jonchere B; Chai SC; Connelly M; Waddell MB; Das S; Neale G; Li Z; Shadrick WR; Olsen RR; Freeman KW; Low JA; Price JE; Young BM; Bharatham N; Boyd VA; Yang J; Lee RE; Morfouace M; Roussel MF; Chen T; Savic D; Guy RK; White SW; Shelat AA; Potter PM
    Cancer Res; 2020 Sep; 80(17):3507-3518. PubMed ID: 32651255
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Binding pocket-based design, synthesis and biological evaluation of novel selective BRD4-BD1 inhibitors.
    Ma J; Chen H; Yang J; Yu Z; Huang P; Yang H; Zheng B; Liu R; Li Q; Hu G; Chen Z
    Bioorg Med Chem; 2019 May; 27(9):1871-1881. PubMed ID: 30926312
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Selectivity Mechanism of Pyrrolopyridone Analogues Targeting Bromodomain 2 of Bromodomain-Containing Protein 4 from Molecular Dynamics Simulations.
    Shi M; Zheng X; Zhou Y; Yin Y; Lu Z; Zou Z; Hu Y; Liang Y; Chen T; Yang Y; Jing M; Lei D; Yang P; Li X
    ACS Omega; 2023 Sep; 8(37):33658-33674. PubMed ID: 37744850
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A theoretical insight into selectivity of inhibitors toward two domains of bromodomain-containing protein 4 using molecular dynamics simulations.
    Su J; Liu X; Zhang S; Yan F; Zhang Q; Chen J
    Chem Biol Drug Des; 2018 Mar; 91(3):828-840. PubMed ID: 29139214
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A bromodomain-DNA interaction facilitates acetylation-dependent bivalent nucleosome recognition by the BET protein BRDT.
    Miller TC; Simon B; Rybin V; Grötsch H; Curtet S; Khochbin S; Carlomagno T; Müller CW
    Nat Commun; 2016 Dec; 7():13855. PubMed ID: 27991587
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Toward more potent imidazopyridine inhibitors of Candida albicans Bdf1: Modeling the role of structural waters in selective ligand binding.
    Zhou Y; Overhulse JM; Dupper NJ; Guo Y; Kashemirov BA; Wei K; Govin J; Petosa C; McKenna CE
    J Comput Chem; 2022 Dec; 43(32):2121-2130. PubMed ID: 36190786
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structure-Guided Design and Synthesis of Pyridinone-Based Selective Bromodomain and Extra-Terminal Domain (BET)-First Bromodomain (BD1) Inhibitors.
    Li Y; Shen Z; Ratia K; Zhao J; Huang F; Dubrovyskyii O; Indukuri D; Fu J; Lozano Ramos O; Thatcher GRJ; Xiong R
    J Med Chem; 2024 Feb; 67(4):2712-2731. PubMed ID: 38295759
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structure-Guided Design of a Domain-Selective Bromodomain and Extra Terminal N-Terminal Bromodomain Chemical Probe.
    Bradley E; Fusani L; Chung CW; Craggs PD; Demont EH; Humphreys PG; Mitchell DJ; Phillipou A; Rioja I; Shah RR; Wellaway CR; Prinjha RK; Palmer DS; Kerr WJ; Reid M; Wall ID; Cookson R
    J Med Chem; 2023 Dec; 66(23):15728-15749. PubMed ID: 37967462
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structure investigation, enrichment analysis and structure-based repurposing of FDA-approved drugs as inhibitors of BET-BRD4.
    Wakchaure P; Velayutham R; Roy KK
    J Biomol Struct Dyn; 2019 Aug; 37(12):3048-3057. PubMed ID: 30079805
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular docking and dynamics simulation study of flavonoids as BET bromodomain inhibitors.
    Raj U; Kumar H; Varadwaj PK
    J Biomol Struct Dyn; 2017 Aug; 35(11):2351-2362. PubMed ID: 27494802
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Domain-Selective BET Ligands Yield Next-Generation Synthetic Genome Readers/Regulators with Nonidentical Cellular Functions.
    Mohammed A; Waddell MB; Sutkeviciute I; Danda A; Philips SJ; Lang W; Slavish PJ; Kietlinska SJ; Kaulage M; Sourav D; Ansari AZ
    J Am Chem Soc; 2023 Nov; ():. PubMed ID: 37923569
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery of Benzo[d]imidazole-6-sulfonamides as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the First Bromodomain.
    Cipriano A; Milite C; Feoli A; Viviano M; Pepe G; Campiglia P; Sarno G; Picaud S; Imaide S; Makukhin N; Filippakopoulos P; Ciulli A; Castellano S; Sbardella G
    ChemMedChem; 2022 Oct; 17(20):e202200343. PubMed ID: 36040095
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structural and biochemical insights into purine-based drug molecules in hBRD2 delineate a unique binding mode opening new vistas in the design of inhibitors of the BET family.
    Arole AH; Deshmukh P; Sridhar A; Mathur S; Mahalingaswamy M; Subramanya H; Dalavaikodihalli Nanjaiah N; Padmanabhan B
    Acta Crystallogr D Struct Biol; 2023 Aug; 79(Pt 8):758-774. PubMed ID: 37432115
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Selective inhibition mechanism of nitroxoline to the BET family: Insight from molecular simulations.
    Zhu M; Song LT; Liu RR; Zhai HL; Meng YJ; Ren CL
    Life Sci; 2021 Apr; 270():119141. PubMed ID: 33529672
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Novel Phenanthridionone Based Scaffold As a Potential Inhibitor of the BRD2 Bromodomain: Crystal Structure of the Complex.
    Tripathi S; Mathur S; Deshmukh P; Manjula R; Padmanabhan B
    PLoS One; 2016; 11(5):e0156344. PubMed ID: 27243809
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous Proteins.
    Taniguchi Y
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27827996
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.